{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:14:53Z","timestamp":1764936893346},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Samples of acral lentiginous melanomas (ALMs) were obtained from the Department of Pathology at Escola Paulista de Medicina\u2014Universidade Federal de S\u00e3o Paulo (UNIFESP), S\u00e3o Paulo, Brazil. Demographic, clinical, and follow-up data were obtained from the charts of Hospital S\u00e3o Paulo. From 2 tissue microarrays containing 60 nevi and quadruplicate samples of \u22651.0-mm of 49 ALM, sections were stained to evaluate SCF, KIT, BRAF, CYCLIND1, MYC, and PTEN immunohistochemical protein expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Nevi and ALM from 2006 to 2010 were reviewed and collected. All specimens were in the vertical growth phase, and histopathological parameters indicated that tumors were at an advanced stage at diagnosis. Average tumor thickness was 6.95 mm, 63% were ulcerated, average mitotic index was 5 mitotic cells per mm<jats:sup>2<\/jats:sup>, and 43% were at Clark's level V. Compared with nevi, the \u03c7<jats:sup>2<\/jats:sup> test showed that ALM significantly correlated with SCF protein expression (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001) and expression heterogeneity (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.000). Similar findings were observed for KIT (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.005, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003, respectively), MYC (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.000, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.000), and PTEN (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.005, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.000). Malignancy did not correlate with BRAF and CYCLIN D1 expression (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.053 and <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.259, respectively), but it did significantly correlate with their heterogeneous expression (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.000, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.024, respectively). Combined protein expression had an odds ratio of greater malignancy when BRAF and MYC were positive and\/or heterogeneously expressed (OR of 78 and 95, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion and Conclusion:<\/jats:title>\n            <jats:p>We show that marker protein expression, when combined with heterogeneous expression as shown by immunohistochemistry, is a powerful indicator of malignancy in ALMs, especially, when protein pairs are combined.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dad.0000000000000635","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T11:33:39Z","timestamp":1486726419000},"page":"114-120","source":"Crossref","is-referenced-by-count":9,"title":["Marker Protein Expression Combined With Expression Heterogeneity is a Powerful Indicator of Malignancy in Acral Lentiginous Melanomas"],"prefix":"10.1097","volume":"39","author":[{"given":"Fernando","family":"Cintra Lopes Carapeto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9ia","family":"Neves Comodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andressa","family":"Germano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiane","family":"Pereira Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Barcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Landman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1535-7163.MCT-12-0530","article-title":"Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine","volume":"11","author":"Wilmott","year":"2012","journal-title":"Mol Cancer Ther."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2006.06.0442","article-title":"Toward a molecular classification of melanoma","volume":"25","author":"Fecher","year":"2007","journal-title":"J Clin Oncol."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma","volume":"38","author":"Menzies","year":"2014","journal-title":"Am J Surg Pathol."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2303.2002.00376.x","article-title":"Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma","volume":"13","author":"Sviatoha","year":"2002","journal-title":"Cytopathology"},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0002-9440(10)64075-8","article-title":"Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors","volume":"158","author":"Hoos","year":"2001","journal-title":"Am J Pathol."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.3748\/wjg.v18.i23.2929","article-title":"Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth","volume":"18","author":"Bai","year":"2012","journal-title":"World J Gastroenterol."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"Long","year":"2013","journal-title":"Am J Surg Pathol."},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/DAD.0b013e31821ec0ef","article-title":"Lack of correlation between immunohistochemical expression of CKIT and KIT mutations in atypical acral nevi","volume":"34","author":"Park","year":"2012","journal-title":"Am J Dermatopathol."},{"key":"R11-20230908","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":"Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous\/mucosal type","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol."},{"key":"R12-20230908","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00008390-200402000-00006","article-title":"Validation of tissue microarray for the immunohistochemical profiling of melanoma","volume":"14","author":"Pacifico","year":"2004","journal-title":"Melanoma Res."},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-0560.2007.00891.x","article-title":"Immunohistochemical characteristics of melanoma","volume":"35","author":"Ohsie","year":"2008","journal-title":"J Cutan Pathol."},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ijc.24048","article-title":"Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas","volume":"124","author":"Ashida","year":"2009","journal-title":"Int J Cancer."},{"key":"R15-20230908","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.jid.5700125","article-title":"Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes","volume":"126","author":"Alexeev","year":"2006","journal-title":"J Invest Dermatol."},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"31769","DOI":"10.1074\/jbc.M403907200","article-title":"Roles of stem cell factor\/c-Kit and effects of Glivec\/STI571 in human uveal melanoma cell tumorigenesis","volume":"279","author":"Lefevre","year":"2004","journal-title":"J Biol Chem."},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma","volume":"38","author":"Menzies","year":"2014","journal-title":"Am J Surg Pathol."},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jnci\/djt119","article-title":"Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia","volume":"105","author":"Yeh","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1200\/JCO.2005.14.415","article-title":"Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies","volume":"23","author":"Lorusso","year":"2005","journal-title":"J Clin Oncol."},{"key":"R21-20230908","first-page":"2170","article-title":"Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization","volume":"58","author":"Bastian","year":"1998","journal-title":"Cancer Res."},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med."},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1677\/erc.0.0070143","article-title":"c-Myc in breast cancer","volume":"7","author":"Liao","year":"2000","journal-title":"Endocr Relat Cancer."},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1054\/bjps.1998.3024","article-title":"Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma","volume":"52","author":"Grover","year":"1999","journal-title":"Br J Plast Surg."},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/cyto.b.20016","article-title":"Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation","volume":"60","author":"Treszl","year":"2004","journal-title":"Cytometry B Clin Cytom."},{"key":"R26-20230908","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1038\/onc.2014.262","article-title":"Single-cell gene expression signatures reveal melanoma cell heterogeneity","volume":"34","author":"Ennen","year":"2015","journal-title":"Oncogene"},{"key":"R27-20230908","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":"Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma","volume":"122","author":"Tsao","year":"2004","journal-title":"J Invest Dermatol."},{"key":"R28-20230908","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1947601910373795","article-title":"The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-\u03baB\/Snail\/RKIP\/PTEN circuit","volume":"1","author":"Lin","year":"2010","journal-title":"Genes Cancer."},{"key":"R29-20230908","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/hmg\/10.6.599","article-title":"PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model","volume":"10","author":"Weng","year":"2001","journal-title":"Hum Mol Genet."},{"key":"R30-20230908","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201702000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T04:08:20Z","timestamp":1694146100000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201702000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000635","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}